Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | Human cathelicidin, hCAP-18 C-terminal peptide, Cathelicidin antimicrobial peptide (CAMP), CAP18 |
| Category | Immune Modulation |
| Formula | C₂₀₅H₃₄₀N₆₀O₅₃ |
| Molecular weight | 4493.33 Da |
| Half-life | route-dependent; minutes to hours |
| Mechanism (summary) | LL-37 is the only human cathelicidin antimicrobial peptide — an endogenous host-defense molecule that sits at the intersection of innate immunity, biofilm control, inflammation, and tissue repair. It has both protective and potentially pro-inflammatory effects, so its literature is unusually dual-sided. |
| Dosing notes | No approved mainstream human LL-37 product with standard dosing instructions exists. Clinical wound studies have used topical application in venous leg ulcers and diabetic foot ulcers, but their formulations do not establish a universal regimen. |
| Storage | No validated, product-specific LL-37 storage standard was located across research suppliers and clinical formulations. Research-grade peptide handling: lyophilized storage at about -20°C or colder, protected from light and moisture, aliquoted with minimal freeze-thaw after reconstitution. |
|---|
| Read more | Full reference → |
|---|